AAV2 variant (Y444F) vector system (retina-validated AAV expression and packaging plasmid system)

GeneMedi’s AAV2 variant (Y444F, Y730F, Y500F, Y27variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) helper-free packaging plasmids system) is including AAV2 variant (Y444F,Y730F,Y500F,Y272F,Y704F,Y252F) Rep-Cap plamid (AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) -RC plasmid), AAV helper plasmid and AAV expression vectors (overexpression or shRNA).

You can choose your suiltable AAV expression vector plasmids from GeneMedi’s AAV expression vector core. The AAV expression vector plasmids were constructed with differernt expression cassettes,containing kinds of verified protomters and reporters including GFP, zsgreen, RFP, mcherry and luciferase. The GeneMedi’s AAV expression vectors have been proved very suitalble for unique gene overexpression or shRNA-mediated knock-down (also called RNAi (RNA interference ). You can also achieve gene knock-out(KO) or gene editing using our Crispr-cas9-gRNA AAV expression vector.

AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) Rep-Cap plamid supplies the AAV2 Rep(replication) proteins and the AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) capsid-engineered protein.

The tissue tropism of AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) vector has been validated in retina (retinal ganglion cells) by both intravitreal injection and sub-retinal injection with potential applications in retina gene therapy.

AAV2 capsid variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) tissue tropism and gene transduction
(serotype-specific AAV infection)

The tissue tropism of AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F) vector has been validated in retina (retinal ganglion cells) by both intravitreal injection and sub-retinal injection with potential applications in retina gene therapy.

Virus and titer: AAV2 variant (Y444F) vector system, 1×10¹² vg/ml
Animal: mouse, C57, 2 months
Infection site: retina
Gene delivery method: subretinal cavity injection, 3μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy